Review article · 2025 · Open access

A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics

Stefano Damiani, Aldo D'Imperio, Joaquim Raduà, Lydia Fortea, Matteo Calò, Andrea Crippa, Cecilia Maria Esposito, Estella Linda Luisa Lumer, Sara Patron, Alessandro Peviani, Alessandro Piccolo, Umberto Provenzani and 10 more

Psychiatry Research, 347, 116406 · Published 17 February 2025 · DOI 10.1016/j.psychres.2025.116406

Open full textCite this paper

In brief

“A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics” is a 2025 review article by Stefano Damiani and 21 co-authors, published in Psychiatry Research. OpenAlex counts 7 citations as of 20 November 2026. It is open access under a CC BY licence: the full text is free to read at Psychiatry Research.

Citations
7
Most cited in
2026 (6)
Field-weighted impact
0.76
References
78
Authors
22

Abstract

Negative symptoms in schizophrenia spectrum are associated with minimal treatment responses. The search for effective treatments is potentially hampered by heterogenous study-designs and sample characteristics depending on the intervention category. This PRISMA-compliant systematic review/synthesis aims to describe the literature on negative symptoms interventions for schizophrenia spectrum disorders by comparing 12 study design, demographical and clinical variables in different intervention categories: antipsychotics (AP), other pharmacological agents (OPA), brain stimulation (BS), psychological/psychosocial (PSI), lifestyle (LS), mixed interventions. Kruskal-Wallis and Chi-square tests measured differences between intervention-groups. Out of 19,935 articles, 489 (AP=149/OPA=187/BS=49/PSI=79/LS=19/mixed=6) were selected for data extraction. Concerning study designs, AP had the largest average arm size (mean ± SD=91.1 ± 122.8participants), OPA the highest double/triple-blinding (97.9 %) rates, PSI the longest follow-up (26.7 ± 21.8weeks). Age/gender demographical differences were significant but of negligible magnitude. OPA illness duration (14.8 ± 9.0years) was longer compared to AP (11.4 ± 6.7years). Positive and Negative Syndrome Scale (PANSS) negative scores were milder in PSI (18.6 ± 6.9) compared to AP/OPA/BS (23.8 ± 6.4/23.4 ± 4.9/24.2 ± 9.2). PANSS total scores were worse in AP (83.6 ± 18.2) than in OPA/BS/PSI (77.1 ± 20.5/75.5 ± 14.7/67.0 ± 23.3). The same was true for dropout rates (AP=25.5 %, OPA/BS/PSI=14.3/9.7/14.5 %). Prevalent treatment as usual was "none" for AP (36.7 %) and "antipsychotic" for other categories (42.3-82.8 %). Implementing cross-over, factorial or multi-arm designs may increase the comparability between studies investigating different intervention categories. Concerning clinical differences, reporting individual treatments at baseline and clinical severity, evaluating cognitive profiles and considering patients' perspectives will allow to better understand the efficacy of the available treatments and develop tailored interventions.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Damiani, S., D'Imperio, A., Raduà, J., Fortea, L., Calò, M., Crippa, A., Esposito, C. M., Lumer, E. L. L., Patron, S., Peviani, A., Piccolo, A., Provenzani, U., Santilli, F., Spallarossa, C., Fusar‐Poli, L., Papanastasiou, E., Cella, M., Patel, R., Galderisi, S., . . . Fusar‐Poli, P. (2025). A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics. Psychiatry Research, 347, 116406. https://doi.org/10.1016/j.psychres.2025.116406

MLA 9

Damiani, Stefano, et al. “A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics.” Psychiatry Research, vol. 347, 2025, p. 116406. https://doi.org/10.1016/j.psychres.2025.116406.

Chicago

Damiani, Stefano, Aldo D'Imperio, Joaquim Raduà, Lydia Fortea, Matteo Calò, Andrea Crippa, Cecilia Maria Esposito, et al. 2025. “A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics.” Psychiatry Research 347: 116406. https://doi.org/10.1016/j.psychres.2025.116406.

Harvard

Damiani, S. et al. (2025) ‘A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics’, Psychiatry Research, 347, p. 116406. doi:10.1016/j.psychres.2025.116406.

IEEE

S. Damiani et al., “A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics,” Psychiatry Research, vol. 347, p. 116406, 2025, doi: 10.1016/j.psychres.2025.116406.

BibTeX

@article{damiani2025systematic,
  title     = {{A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics}},
  author    = {Damiani, Stefano and D'Imperio, Aldo and Raduà, Joaquim and Fortea, Lydia and Calò, Matteo and Crippa, Andrea and Esposito, Cecilia Maria and Lumer, Estella Linda Luisa and Patron, Sara and Peviani, Alessandro and Piccolo, Alessandro and Provenzani, Umberto and Santilli, Fabrizio and Spallarossa, Cecilia and Fusar‐Poli, Laura and Papanastasiou, Evangelos and Cella, Matteo and Patel, Rashmi and Galderisi, Silvana and Leucht, Stefan and Stahl, Daniel R. and Fusar‐Poli, Paolo},
  journal   = {Psychiatry Research},
  year      = {2025},
  volume    = {347},
  pages     = {116406},
  doi       = {10.1016/j.psychres.2025.116406},
  url       = {https://doi.org/10.1016/j.psychres.2025.116406}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment

  • negative symptoms
  • schizophrenia spectrum disorders
  • antipsychotic drugs
  • pharmacological agents
  • brain stimulation
  • psychosocial interventions
  • lifestyle intervention
  • study design heterogeneity

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Damiani, S., D'Imperio, A., Raduà, J., Fortea, L., Calò, M., Crippa, A., Esposito, C. M., Lumer, E. L. L., Patron, S., Peviani, A., Piccolo, A., Provenzani, U., Santilli, F., Spallarossa, C., Fusar‐Poli, L., Papanastasiou, E., Cella, M., Patel, R., Galderisi, S., . . . Fusar‐Poli, P. (2025). A systematic review and synthesis of 489 studies investigating treatments for negative symptoms in the schizophrenia spectrum: Trial designs, demographics and clinical characteristics. Psychiatry Research, 347, 116406. https://doi.org/10.1016/j.psychres.2025.116406

How many times has this paper been cited?

7 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Psychiatry Research: sign in and open the full text from this page.

Who wrote this paper?

Stefano Damiani, Aldo D'Imperio, Joaquim Raduà, Lydia Fortea, Matteo Calò, Andrea Crippa, Cecilia Maria Esposito, Estella Linda Luisa Lumer, Sara Patron, Alessandro Peviani, Alessandro Piccolo, Umberto Provenzani and 10 more.

What is the DOI of this paper?

10.1016/j.psychres.2025.116406, permanently at https://doi.org/10.1016/j.psychres.2025.116406. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.